IQV

IQVIA Holdings Inc

Healthcare


Presented:09/26/2017
Price:$94.08
Cap:$20.91B
Current Price:$232.98
Cap:$42.47B

Presented

Date09/26/2017
Price$94.08
Market Cap$20.91B
Ent Value$28.14B
P/E Ratio128.95x
Book Value$34.84
Div Yield0%
Shares O/S222.30M
Ave Daily Vol1,846,854
Short Int2.58%

Current

Price$232.98
Market Cap$42.47B
IQVIA Holdings Inc is a biotechnology company, which engages in healthcare development in the provision of professional services, information technology, and partnering solutions to the pharmaceutical services and healthcare industries. The company was founded by Dennis Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Please note, on 11/15/17 QuintilesIMS (Q) changed its company name and ticker to IQVIA Holdings Inc (IQV). The content of this idea will make reference to the original company name and ticker symbol.

Publicly traded companies mentioned herein: Quintiles IMS Holdings Inc (Q), Laboratory Corp of America Holdings (LH), PRA Health Sciences Inc (PRAH)

Highlights

The presenter was “intrigued” with the merger of Quintiles (Q) and IMS when the deal was announced (May 2016) because there was a considerable amount of skepticism in the market about the rationale for the combination. While the proof-of-concept is playing out today, initial indications are positive and he is long the stock in the mid-$90s. If the value proposition is real, there is meaningful upside potential for shareholders that are willing to wait and see how the benefits of the new strategy play out. The combination of IMS’ prescription data and Quintiles’ leading contract research (CRO) services could lead to better/ faster clinical trial enrollment, and thus accelerated approvals for the company’s customers. If QuintilesIMS’ Chairman and CEO Ari Bousbib - and his team - can execute, the presenter has a high degree of confidence that Q will gain share, grow revenue, expand margins, and see its multiple rise over the next 12-24 months. If his model is accurate, EPS should see a 15-17% CAGR, and the stock could trade up to $120+ for a 25% gain with little downside risk.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.